News

Polykon Manufacturing LLC merges with Seppic Inc. and becomes Seppic Inc. Richmond

Since its opening in 2020 in Richmond, Virginia, the Polykon Manufacturing LLC facility has strengthened Seppic’s proximity to our North American customers and expanded our manufacturing capabilities. Effective January 1, 2024, Polykon Manufacturing LLC took the next step by merging with its parent company, Seppic Inc.

This change brings consistency to the organization of Seppic’s manufacturing facilities and supports the company’s strategy to deliver a simplified customer experience. Seppic continues to grow by addressing multiple markets around the world, always with the highest level of service, while strengthening its brand image in the United States.

Seppic Inc. Richmond produces in particular SEPIMAX ZEN™, SEPINOV™ EMT 10, SEPINOV™ WEO, SIMULGEL™ NS, or SIMULGEL INS 100™. As a major global player in rheology modifiers, the Seppic Group continually invests in its production facilities in the United States to provide a high level of service to its customers.

Recent News

09/03/2026

Seppic announces the appointment of Virginie Cavalli as Chief Executive Officer

A subsidiary of Air Liquide Healthcare, Seppic designs, manufactures, and distributes a wide range of specialty ingredients used in cosmetics, nutraceuticals, pharmaceuticals, veterinary products, and industrial applications. Nearly 900 employees support customers in 100 countries through the company’s subsidiaries and distributor network. With a degree from EMLyon school in business and financial strategy, Virginie Cavalli

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the